(UroToday.com) The combination chemotherapy regimen of paclitaxel, ifosfamide, and cisplatin (TIP) for four cycles was published as a regimen for favorable risk progressive metastatic germ cell tumors in 20051 based on a 46-patient study with 70% achieving a complete response and a 2-year progression-free survival rate of 65%. Favorable risk was classified as only one prior regimen of cisplatin-containing therapy (less than 6 cycles), primary gonadal tumor site, and either complete response or partial response with normal tumor markers that persisted for more than 6 months after first-line chemotherapy. In this presentation, Dr. Jack Gleeson presents the long-term follow-up of the original 46 patients, as well as results from both an expansion cohort of 41 patients that would have met the original study’s inclusion criteria and 17 patients that did not have at least one of the MSKCC favorable risk factors.